breast cancer

[Cellular and Molecular Life Sciences] Scientists provide a comprehensive review of clinical significance of mesenchymal circulating tumor cells in breast cancer together with statistical analysis of previously published data.

[Science Translational Medicine] Investigators found that distant metastases were more immune inert with increased M2 macrophages compared to their matched primary tumors.

[Veru, Inc.] Veru, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and company which will evaluate the efficacy and safety of enobosarm in combination with Lilly’s abemaciclib as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer

[Journal of Cellular Physiology] Ubiquitin-specific peptidase 5 (USP5) stabilized hypoxia-inducible factor 2α (HIF2α) through its deubiquitinase activity and provided a potential therapeutic target for breast cancer.

[Cell Death & Disease] Overexpression of RBM5-AS1 facilitated proliferation, migration, invasion, EMT, and stemness maintenance of breast cancer cells in vitro and in vivo.

[Cell Death & Disease] Scientists depicted the mechanism of breast cancer stem cells’ (bCSCs) response to replication stress (RS) and its clinical implication, and demonstrated that bCSCs presented a limited level of RS compared with non-bCSCs in patient samples.